

Status: Currently Official on 14-Feb-2025
Official Date: Official Prior to 2013
Document Type: USP Monographs
DocId: GUID-5AF8323C-B338-4EF7-9010-77B05A6AB44F_1_en-US
DOI: https://doi.org/10.31003/USPNF_M13994_01_01
DOI Ref: r6pjz

© 2025 USPC
Do not distribute

Cefixime Tablets

DEFINITION

Cefixime Tablets contain the equivalent of NLT 90.0% and NMT 110.0% of the labeled amount of cefixime ($C_{16}H_{15}N_5O_7S_2$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: 25 mL of 0.4 M tetrabutylammonium hydroxide solution diluted with water to 1000 mL, and adjusted with 1.5 M phosphoric acid to a pH of 6.5

Solution B: 13.6 g/L of monobasic potassium phosphate in water

Solution C: 14.2 g/L of anhydrous dibasic sodium phosphate in water

Buffer: Adjust an aliquot of *Solution C* with *Solution B* to a pH of 7.0.

Mobile phase: Acetonitrile and *Solution A* (1:3)

System suitability solution: 1 mg/mL of [USP Cefixime RS](#) in water. Heat this solution at 95° in an oil bath for 45 min, cool, and use promptly.

Standard solution: 0.2 mg/mL of [USP Cefixime RS](#) in *Buffer*. Use this solution promptly.

Sample stock solution: Nominally 4 mg/mL of cefixime in *Buffer* from finely powdered Tablets (NLT 20). Sonicate as required, and centrifuge.

Sample solution: Nominally 0.2 mg/mL of cefixime from *Sample stock solution* in *Buffer*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 12.5-cm; 4-μm packing L1

Column temperature: 40°

Flow rate: Adjusted so that the retention time of cefixime is about 10 min

Injection volume: 10 μL

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for cefixime (*E*)-isomer and cefixime are about 0.9 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 2.0 between cefixime and cefixime (*E*)-isomer, *System suitability solution*

Column efficiency: NLT 4000 theoretical plates for the *Standard solution*

Calculate as follows:

$$\text{Result} = 5.545(t/W_{h/2})^2$$

t = retention time

$W_{h/2}$ = peak width at half height

Tailing factor: NLT 0.9 and NMT 2.0 for the analyte peak

Calculate as follows:

$$\text{Result} = W_{0.1}/2f$$

$W_{0.1}$ = width of peak of 10% height

f = distance from the peak maximum to the leading edge of the peak measured at 10% of the peak height

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of cefixime ($C_{16}H_{15}N_5O_7S_2$) in the portion of Tablets taken:

- r_U = peak response from the *Sample solution*
- r_S = peak response from the *Standard solution*
- C_S = concentration of [USP Cefixime RS](#) in the *Standard solution* (mg/mL)
- C_U = nominal concentration of cefixime in the *Sample solution* (mg/mL)
- P = potency of cefixime in [USP Cefixime RS](#) (mg/mg)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [DISSOLUTION \(711\)](#)**
Medium: 6.8 g/L of monobasic potassium phosphate in water, adjusted with 1 N sodium hydroxide to a pH of 7.2; 900 mL
Apparatus 1: 100 rpm
Time: 45 min
Detector: UV 288 nm
Standard solution: [USP Cefixime RS](#) in *Medium*. An amount of methanol not to exceed 0.1% of the total volume of the *Standard solution* may be used to bring the [USP Cefixime RS](#) into solution before dilution with *Medium*, and the solution may be sonicated to ensure complete dissolution of the [USP Cefixime RS](#).
Sample solution: Sample per [Dissolution \(711\)](#). Dilute with *Medium* to a concentration similar to that of the *Standard solution*.
Tolerances: NLT 75% (Q)
- [UNIFORMITY OF DOSAGE UNITS \(905\)](#):** Meet the requirements

SPECIFIC TESTS

- [WATER DETERMINATION, Method I \(921\)](#):** NMT 10.0%

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE:** Preserve in tight containers.
- LABELING:** Label the Tablets to indicate that the cefixime contained therein is in the trihydrate form.
- [USP REFERENCE STANDARDS \(11\)](#)**
[USP Cefixime RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CEFIXIME TABLETS	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(1)

Current DocID: GUID-5AF8323C-B338-4EF7-9010-77B05A6AB44F_1_en-US

DOI: https://doi.org/10.31003/USPNF_M13994_01_01

DOI ref: [r6pjz](#)